HAVCR2 and colorectal carcinoma: In T lymphocytes isolated from sporadic CRC patients, the co-blockade of TIM-3 and PD1, the target of the immune checkpoint inhibitor nivolumab and pembrolizumab, not only increased the frequency of IFNγ- and TNFα-secreting T cells and the proliferation of tumor antigen-specific CD8+ cells but also reduced the number of Tregs [123].